In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
Puma Biotechnology Inc (NASDAQ: PBYI) closed the day trading at $4.87 up 0.41% from the previous closing price of $4.85. In other words, the price has increased by $0.41 from its previous closing price. On the day, 1.64 million shares were traded. PBYI stock price reached its highest trading level at $4.98 during the session, while it also had its lowest trading level at $4.66.
Ratios:
For a better understanding of PBYI, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.50 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 5.55. For the most recent quarter (mrq), Quick Ratio is recorded 1.62 and its Current Ratio is at 1.73. In the meantime, Its Debt-to-Equity ratio is 0.47 whereas as Long-Term Debt/Eq ratio is at 0.10.
Goldman Downgraded its Neutral to Sell on October 08, 2019, whereas the target price for the stock was revised from $24 to $8.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 18 ’25 when Cesano Alessandra sold 27,000 shares for $3.37 per share. The transaction valued at 90,909 led to the insider holds 41,850 shares of the business.
Cesano Alessandra bought 27,000 shares of PBYI for $90,909 on Jul 18 ’25. On Jul 08 ’25, another insider, NOUGUES MAXIMO F, who serves as the Chief Financial Officer of the company, sold 5,587 shares for $3.53 each. As a result, the insider received 19,739 and left with 208,164 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PBYI now has a Market Capitalization of 245305296 and an Enterprise Value of 198511424. As of this moment, Puma’s Price-to-Earnings (P/E) ratio for their current fiscal year is 4.97, and their Forward P/E ratio for the next fiscal year is 15.08. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.03 while its Price-to-Book (P/B) ratio in mrq is 2.32. Its current Enterprise Value per Revenue stands at 0.834 whereas that against EBITDA is 3.462.
Stock Price History:
The Beta on a monthly basis for PBYI is 1.30, which has changed by 0.79044116 over the last 52 weeks, in comparison to a change of 0.18157876 over the same period for the S&P500. Over the past 52 weeks, PBYI has reached a high of $5.06, while it has fallen to a 52-week low of $2.22. The 50-Day Moving Average of the stock is 40.39%, while the 200-Day Moving Average is calculated to be 53.89%.
Shares Statistics:
Over the past 3-months, PBYI traded about 433.17K shares per day on average, while over the past 10 days, PBYI traded about 915050 shares per day. A total of 49.89M shares are outstanding, with a floating share count of 37.93M. Insiders hold about 24.71% of the company’s shares, while institutions hold 54.22% stake in the company. Shares short for PBYI as of 1753920000 were 2784330 with a Short Ratio of 6.43, compared to 1751241600 on 2633554. Therefore, it implies a Short% of Shares Outstanding of 2784330 and a Short% of Float of 6.529999999999999.
Earnings Estimates
Its stock is currently analyzed by 1.0 different market analysts. The consensus estimate for the next quarter is $0.36, with high estimates of $0.36 and low estimates of $0.36.
Analysts are recommending an EPS of between $0.7 and $0.7 for the fiscal current year, implying an average EPS of $0.7. EPS for the following year is $0.65, with 1.0 analysts recommending between $0.65 and $0.65.
Revenue Estimates
1 analysts predict $51M in revenue for the current quarter. It ranges from a high estimate of $51M to a low estimate of $51M. As of the current estimate, Puma Biotechnology Inc’s year-ago sales were $80.5MFor the next quarter, 1 analysts are estimating revenue of $66.6M. There is a high estimate of $66.6M for the next quarter, whereas the lowest estimate is $66.6M.
A total of 1 analysts have provided revenue estimates for PBYI’s current fiscal year. The highest revenue estimate was $216M, while the lowest revenue estimate was $216M, resulting in an average revenue estimate of $216M. In the same quarter a year ago, actual revenue was $230.5MBased on 1 analysts’ estimates, the company’s revenue will be $218M in the next fiscal year. The high estimate is $218M and the low estimate is $218M.
